Merck KGaA (MRK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Merck KGaA (MRK) has a cash flow conversion efficiency ratio of 0.045x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€1.29 Billion ≈ $1.51 Billion USD) by net assets (€28.66 Billion ≈ $33.51 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MRK net asset quality score to measure how much of total assets are equity-financed.
Merck KGaA - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Merck KGaA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check MRK cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Merck KGaA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Merck KGaA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Telefónica S.A
F:TNE2
|
0.166x |
|
Dow Inc
NYSE:DOW
|
0.067x |
|
Jiangsu Hengli Hydraulic Co Ltd
SHG:601100
|
0.021x |
|
Omnicom Group Inc
NYSE:OMC
|
-0.055x |
|
AXIA Energia SA
NYSE:AXIA-PC
|
0.023x |
|
Church & Dwight Company Inc
NYSE:CHD
|
0.042x |
|
Telefonica SA ADR
NYSE:TEF
|
0.115x |
|
Lundin Mining Corporation
TO:LUN
|
0.060x |
Annual Cash Flow Conversion Efficiency for Merck KGaA (2002–2025)
The table below shows the annual cash flow conversion efficiency of Merck KGaA from 2002 to 2025. For the full company profile with market capitalisation and key ratios, see Merck KGaA (MRK) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €28.66 Billion ≈ $33.51 Billion |
€3.93 Billion ≈ $4.60 Billion |
0.137x | -10.29% |
| 2024-12-31 | €29.99 Billion ≈ $35.06 Billion |
€4.59 Billion ≈ $5.36 Billion |
0.153x | +8.13% |
| 2023-12-31 | €26.75 Billion ≈ $31.28 Billion |
€3.78 Billion ≈ $4.42 Billion |
0.141x | -13.64% |
| 2022-12-31 | €26.00 Billion ≈ $30.40 Billion |
€4.26 Billion ≈ $4.98 Billion |
0.164x | -24.02% |
| 2021-12-31 | €21.42 Billion ≈ $25.04 Billion |
€4.62 Billion ≈ $5.40 Billion |
0.216x | +5.49% |
| 2020-12-31 | €17.02 Billion ≈ $19.89 Billion |
€3.48 Billion ≈ $4.06 Billion |
0.204x | +28.15% |
| 2019-12-31 | €17.91 Billion ≈ $20.94 Billion |
€2.86 Billion ≈ $3.34 Billion |
0.159x | +23.82% |
| 2018-12-31 | €17.23 Billion ≈ $20.15 Billion |
€2.22 Billion ≈ $2.59 Billion |
0.129x | -32.82% |
| 2017-12-31 | €14.07 Billion ≈ $16.44 Billion |
€2.70 Billion ≈ $3.15 Billion |
0.192x | +6.95% |
| 2016-12-31 | €14.05 Billion ≈ $16.43 Billion |
€2.52 Billion ≈ $2.94 Billion |
0.179x | +4.95% |
| 2015-12-31 | €12.86 Billion ≈ $15.03 Billion |
€2.20 Billion ≈ $2.57 Billion |
0.171x | -25.52% |
| 2014-12-31 | €11.80 Billion ≈ $13.80 Billion |
€2.71 Billion ≈ $3.16 Billion |
0.229x | +14.03% |
| 2013-12-31 | €11.07 Billion ≈ $12.94 Billion |
€2.23 Billion ≈ $2.60 Billion |
0.201x | -15.30% |
| 2012-12-31 | €10.41 Billion ≈ $12.18 Billion |
€2.47 Billion ≈ $2.89 Billion |
0.237x | +95.95% |
| 2011-12-31 | €10.49 Billion ≈ $12.27 Billion |
€1.27 Billion ≈ $1.49 Billion |
0.121x | -29.51% |
| 2010-12-31 | €10.37 Billion ≈ $12.13 Billion |
€1.78 Billion ≈ $2.08 Billion |
0.172x | +19.24% |
| 2009-12-31 | €9.51 Billion ≈ $11.12 Billion |
€1.37 Billion ≈ $1.60 Billion |
0.144x | +35.42% |
| 2008-12-31 | €9.62 Billion ≈ $11.25 Billion |
€1.02 Billion ≈ $1.20 Billion |
0.106x | -24.10% |
| 2007-12-31 | €8.69 Billion ≈ $10.16 Billion |
€1.22 Billion ≈ $1.42 Billion |
0.140x | -34.22% |
| 2006-12-31 | €3.81 Billion ≈ $4.45 Billion |
€811.70 Million ≈ $948.96 Million |
0.213x | -3.11% |
| 2005-12-31 | €3.33 Billion ≈ $3.89 Billion |
€732.50 Million ≈ $856.37 Million |
0.220x | +11.57% |
| 2004-12-31 | €2.89 Billion ≈ $3.38 Billion |
€570.90 Million ≈ $667.44 Million |
0.197x | -38.07% |
| 2003-12-31 | €2.36 Billion ≈ $2.76 Billion |
€752.40 Million ≈ $879.63 Million |
0.318x | +55.07% |
| 2002-12-31 | €2.05 Billion ≈ $2.40 Billion |
€421.70 Million ≈ $493.01 Million |
0.205x | -- |
About Merck KGaA
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for re… Read more